114 related articles for article (PubMed ID: 29115587)
41. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
[TBL] [Abstract][Full Text] [Related]
43. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
44. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
[TBL] [Abstract][Full Text] [Related]
45. Advances in proteomics in diffuse large B‑cell lymphoma (Review).
Guo Z; Wang C; Shi X; Wang Z; Tao J; Ma J; Bi L
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38757403
[TBL] [Abstract][Full Text] [Related]
46. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
[TBL] [Abstract][Full Text] [Related]
47. Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway.
Li X; Wang X; Zhang M; Li A; Sun Z; Yu Q
Cell Biochem Biophys; 2014 Nov; 70(2):1357-62. PubMed ID: 24902540
[TBL] [Abstract][Full Text] [Related]
48. ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma.
Xie W; Wu M; Fu T; Li X; Wang Z; Hu Y; Zhu L; Zhang G
Gene; 2017 Sep; 627():255-262. PubMed ID: 28629825
[TBL] [Abstract][Full Text] [Related]
49. Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy.
Yuan H; He M; Cheng F; Bai R; da Silva SR; Aguiar RC; Gao SJ
Oncotarget; 2017 Feb; 8(9):14912-14924. PubMed ID: 28118604
[TBL] [Abstract][Full Text] [Related]
50. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
51. [Corrigendum] Anticancer effect of quinacrine on diffuse large B‑cell lymphoma via inhibition of MSI2‑NUMB signaling pathway.
Yang S; Sheng L; Xu K; Wang Y; Zhu H; Zhang P; Mu Q; Ouyang G
Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33398369
[TBL] [Abstract][Full Text] [Related]
52. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression.
Changchien JJ; Chen YJ; Huang CH; Cheng TL; Lin SR; Chang LS
Toxicol Appl Pharmacol; 2015 Apr; 284(1):33-41. PubMed ID: 25684043
[TBL] [Abstract][Full Text] [Related]
53. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
54. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
[TBL] [Abstract][Full Text] [Related]
55. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
[TBL] [Abstract][Full Text] [Related]
56. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
57. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
[TBL] [Abstract][Full Text] [Related]
58. Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade.
Preet R; Siddharth S; Satapathy SR; Das S; Nayak A; Das D; Wyatt MD; Kundu CN
Biochem Pharmacol; 2016 Apr; 105():23-33. PubMed ID: 26850987
[TBL] [Abstract][Full Text] [Related]
59. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
60. CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
Kim JH; Kim WS; Ryu K; Kim SJ; Park C
Leuk Lymphoma; 2016; 57(6):1413-22. PubMed ID: 26699656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
